Retinal Vein Occlusion and Diabetic Macular Oedema Research Pipeline

According to NIH funding data, a moderate amount of public research funding has been directed toward Retinal Vein Occlusion and Diabetic Macular Oedema, which suggests these conditions have attracted meaningful scientific attention at a global level. However, the direction of that funding has been falling year on year, meaning the financial commitment from public sources appears to be declining rather than growing. For patients, this could mean that research momentum supported by government dollars may be slowing, though it does not tell us what private or industry-funded research may be underway alongside it.

Registry data shows activity across both early and late trial stages, which is an encouraging sign for patients. Early stage trials, such as Phase 1 and Phase 2, suggest researchers are still exploring new approaches, while later stage trials point to treatments that have already cleared initial safety and effectiveness hurdles and are being tested more rigorously. This spread of activity across the pipeline suggests the field has not stalled at a single point, and that some experimental options may be closer to broader availability than others.

For Australian patients, the picture around local access is currently unclear based on the data available. No TGA approval is recorded for treatments in this specific pipeline context, and no PBS listing status has been captured, meaning it is not possible to confirm from this data alone whether any pipeline treatments are approved or subsidised for use in Australia. Patients are encouraged to speak with their specialist about what options may already be available to them and whether any clinical trials are currently recruiting in Australia. This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.